# Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/afatinib-versus-placebo-for-patients-with-advanced-metastatic-non-small-cell/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Vincent A. Miller,Vera Hirsh,Jacques Cadranel,Yuh-Min Chen,Keunchil Park,Sang-We Kim,Caicun Zhou,Wu‐Chou Su,Mengzhao Wang,Yan Sun,Dae Seog Heo,Lucio Crinò,Eng-Huat Tan,Tsu-Yi Chao,Mehdi Shahidi,Xiuyu Julie Cong,Robert M. Lorence,James Chih‐Hsin Yang |
| Citations | 957 |
| DOI | 10.1016/s1470-2045(12)70087-6 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2152905269 |
| PMID | 22452896 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Keunchil Park](https://scholariq.org/researchers/keunchil-park/)
- [Dae Seog Heo](https://scholariq.org/researchers/dae-seog-heo/)
- [Jacques Cadranel](https://scholariq.org/researchers/jacques-cadranel/)
- [James Chih‐Hsin Yang](https://scholariq.org/researchers/james-chih-hsin-yang/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.